Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

AIDS

Volumn 24, Issue 3, 2010, Pages 469-471

  Poveda, Eva ^a   Anta, Lourdes ^a   Blanco, José Luis ^b   Pérez Elías, Maria Jesús ^c   García, Federico ^d   Leal, Manuel ^e   Ribera, Esteban ^f   Gutiérrez, Félix ^g   Soriano, Vincent ^a   De Mendoza, Carmen ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g Hospital General Universitario   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; ETRAVIRINE; NEVIRAPINE;

ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; GENE MUTATION; GENETIC DATABASE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; TREATMENT FAILURE;

ANTI-HIV AGENTS; BENZOXAZINES; DRUG RESISTANCE, VIRAL; HIV-1; HUMANS; MUTATION; NEVIRAPINE; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS; SPAIN; TREATMENT FAILURE;

EID: 75649131140     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328331a4b8     Document Type: Article

References (13)

1. Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, et al. TMC-125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant HIV type 1. Antimicrob Agents Chemother 2004; 48:4680-4686.
2. Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-bind, placebo-controlled trial. Lancet 2007; 370:29-38.
3. Lazzarin A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007; 370:39-48.
4. Vingerhoets J, Buelens A, Peeters M, Picchio G, Tambuyzer L, Van Marck H, et al. Impact of baseline NNRTI mutations on the virological response to TMC-125 in the phase III clinical trials DUET-1 and DUET-2. Antivir Ther 2007; 12 (Suppl): 34.
5. Johnson V, Brun-Vézinet F, Clotet B, Günthard H, Kuritzkes D, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2008. Top HIV Med 2008; 16:138-145.
6. Poveda E, de Mendoza C, Pattery T, Gonzalez M, Villacian J, Soriano V. Phenotypic impact of resistance mutations on etra-virine susceptibility in HIV patients with prior failure to non-nucleoside analogues. AIDS 2008; 22:2395-2398.
7. Vingerhoets J, Peeters M, Azijn H, Tambuyzer L, Hoogstoel A, Nijs S, et al. An update of the list of NNRTI mutations associated with decrease virological response to etravirine: multi-variate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Antivir Ther 2008; 13 (Suppl):A26.
8. de Mendoza C, Anta L, Garcia F, Perez-Elias MJ, Gutierrez F, Llibre JM, et al. HIV-1 genotypic drug resistance interpretation rules: 2009 Spanish guidelines. AIDS Rev 2009; 11:39-51.
9. Anta L, Blanco JL, Pérez-Elias MJ, Garćia F, Leal M, Ribera E, et al. Applications of a national HIV drug resistance database: surveillance and development of genotypic resistance algorithms. 7th European HIV Drug Resistance Workshop; 25-27 March 2009; Stockholm, Sweden; abstract 16.
10. Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, Gonzá-lez- Lahoz J, et al. Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of nonnucleoside reverse transcriptase inhibitors. J Antimicrob Chemother 2007; 60:1411-1413.
11. Llibre JM, Santos J, Puig T, Moltó J, Ruiz L, Paredes R, et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz. J Antimicrob Chemother 2008; 62:909-913.
12. Scott C, Grover D, Nelson M. Is there a role for etravirine in patients with nonnucleoside reverse transcriptase inhibitor resistance? AIDS 2008; 22:989-992.
13. Cahn P, Molina JM, Towner W, Peeters M, Vingerhoets J, Beets G, et al. 48-week pooled analysis of DUET-1 and DUET-2: the impact of baseline characteristics on virological response to etravirine (TMC125; ETR). In: Proceedings of 17th International AIDS Conference; 2008; Mexico City, Mexico; abstract TUPE0047.